American Society of Hirudotherapy

Interstitial Cystitis / Bladder Pain Syndrome (Investigational)

Highly investigational adjunct for IC/BPS refractory to conventional therapy; no clinical study identified; AUA-guideline stepwise therapy remains primary.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for interstitial cystitis / bladder pain syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is highly investigational.
What evidence exists?
No clinical study of leech therapy for this condition was identified in searches of PubMed and Europe PMC. Tier C (highly investigational). Evidence-based management per AUA 2022 guideline is stepwise: behavioral modifications and dietary trigger avoidance, oral pentosan polysulfate (PPS) and amitriptyline, intravesical DMSO or heparin instillations, hydrodistention with cystoscopy, sacral neuromodulation, and selective cyclosporine A for refractory cases. Bladder ulcers (Hunner lesions) benefit from fulguration or triamcinolone injection.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the lower abdomen and sacrum for 5 to 10 days
  • Local skin infection or, rarely, Aeromonas infection
  • Severe allergic reaction in mast-cell-activation prone patients
  • Worsening of bladder pain in the first 24 hours
  • Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
  • Delay of cystoscopy that could identify Hunner lesions or rule out bladder malignancy
  • Delay or replacement of evidence-based AUA-stepwise therapy
Who should not consider this
  • Patients with active urinary tract infection
  • Patients in whom bladder malignancy has not been ruled out by cystoscopy
  • Patients with mast cell activation syndrome with anaphylaxis history
  • Patients within 2 weeks of intravesical therapy
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Patients who have not engaged with first- and second-line AUA-stepwise therapy
What to ask your clinician
  • Has my IC/BPS diagnosis been confirmed (excluded UTI, evaluated for Hunner lesions on cystoscopy if appropriate)?
  • Have I tried behavioral modification, dietary trigger avoidance, and oral PPS or amitriptyline?
  • Have I been offered intravesical DMSO or heparin instillations?
  • Am I a candidate for hydrodistention, sacral neuromodulation, or cyclosporine A?
  • If I have Hunner lesions, have they been fulgurated or injected with triamcinolone?
  • Has the practitioner explained that NO intravesical or genital placement is permitted?
  • What is the practitioner's experience and Aeromonas-prevention plan?
When to seek urgent care
  • New visible blood in urine (especially clots) or unexplained urinary bleeding
  • Inability to urinate (acute retention)
  • Severe pelvic pain with fever, chills (possible UTI, pyelonephritis, or PID)
  • Severe nausea, vomiting, flank pain (possible obstruction or stone)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty (heightened concern in mast-cell-prone patients)

What this does NOT mean

  • This is not FDA-cleared for IC/BPS.
  • With no clinical study identified, efficacy versus AUA-stepwise therapy is NOT established.
  • Mechanism rationale (neurogenic modulation, anti-inflammation) does NOT address urothelial barrier dysfunction or mast-cell-related inflammation.
  • Leech therapy is NEVER intravesical or genital — those placements are absolutely contraindicated.
  • Leech therapy is not a substitute for behavioral modification, oral PPS / amitriptyline, intravesical instillations, or hydrodistention with cystoscopy.

Clinical Profile

Category
Urogenital
ICD-10
N30.10, N30.11
Safety tier
High

Evidence Summary

Interstitial cystitis/bladder pain syndrome is managed per the AUA 2022 guideline as stepwise multimodal therapy: behavioral modification, oral pentosan polysulfate and amitriptyline, intravesical DMSO or heparin, hydrodistention, sacral neuromodulation, and selective cyclosporine for refractory cases. No clinical study of leech therapy for interstitial cystitis/bladder pain syndrome, controlled or uncontrolled, was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov or the Russian- and German-language literature; this is a search result, not proof that none exists. The only mention found is an indication list in the Baskova and Isakhanyan 2004 monograph that names cystitis without patient data. Use is investigational, and the honest evidence grade is D. The complex urothelial-barrier dysfunction and mast-cell-related neurogenic inflammation underlying IC/BPS is unlikely to be directly addressed by peripheral leech application, and any antiinflammatory or neurogenic-modulation rationale remains theoretical.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan name “cystitis” in the list of urological diseases for which, in their words, treatment with leeches is recommended[B1].
  • Interstitial cystitis (painful bladder syndrome) is not named in the book, and nothing at all is said about patients with cystitis — their number, treatment regimens and results: cystitis is only named in a list.
  • In the general description of the urological section, Baskova and Isakhanyan write that, as shown by Savinov, treatment with leeches helps to relieve pain and to resolve the inflammatory process, and further, without a separate reference, that it leads to restoration of the function of the kidneys and the liver and of the trophic state of the bladder, and normalizes urination; this is a general formulation for urological diseases without data on patients, and cystitis is not named in it[B1].
  • Baskova and Isakhanyan call V. A. Savinov a consistent advocate of leeches in urology, but in another chapter they agree with criticism according to which the technologies proposed by him (among other authors) “do not withstand any criticism” from the standpoint of “true naturopathy” and the principle “do no harm” (whether this applies to his urological method is not clear from the text), and in the chapter on contraindications they write that prescribing leeches “in large numbers, for long periods, with no or only short breaks” is unjustified and impermissible[B1].
  • Michalsen et al. do not write about cystitis or bladder diseases.
  • Both books name hemophilia, taking anticoagulants (medicines that affect blood clotting) and anemia as contraindications: Baskova and Isakhanyan include them in their general list of contraindications, while Flecken and Michalsen, in the chapter on contraindications, call hemophilia and anticoagulants an absolute contraindication and regard treatment involving blood loss as generally contraindicated in anemia; this is only part of the contraindications listed in the books[B1][B3].
  • Baskova and Isakhanyan advise refraining from hirudotherapy when body temperature is high, and Flecken and Michalsen write that in the acute stages of infectious diseases leech treatment, according to experience, can cause a feeling of weakness and impair wound healing, and that in the broader concepts of naturopathy and humoral pathology any treatment that extracts blood from patients with infectious diseases is considered counterproductive and is not recommended[B1][B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active urinary tract infection
  • Bladder malignancy (cystoscopy required for diagnosis)
  • Recent intravesical therapy (<2 weeks)
  • Mast cell activation syndrome with anaphylaxis history

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.